The table below shows Krystal Biotech, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
$200.87M
$123.42M
-$88.80M
-$100.57M
-$47.94M
-$26.08M
Capital expenditure
$11.95M
$4.24M
$11.80M
$52.98M
$68.34M
$14.84M
Investing cash flow
-$58.42M
-$163.44M
$82.64M
-$114.08M
-$226.77M
-$11.18M
Dividends paid
-
-
-
-
-
KRYS operating cash flow (10-K history)
Krystal Biotech, Inc. reported operating cash flow of $200.87M for fiscal year 2025. That is up 62.7% from $123.42M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow grew from -$9.45M (FY 2018) to $200.87M. Figures come from the company's audited annual reports as filed with the SEC.
